Formulation of Yuxingcao Injection Veterinary Grade API into parenteral solutions begins with a low-bioburden dry extract of Houttuynia cordata Thunb. aerial parts, not crude herb powder. The extract is pre-dried to a loss-on-drying value below 4.0% w/w before weighing because residual moisture above 5.0% w/w accelerates caking in low-humidity dispensaries. In a 316L stainless-steel vessel passivated per ASTM A967, the extract is dispersed in water for injection at 30–40 °C under a pitched-blade impeller running at 200–400 rpm; undissolved polysaccharide-phenolic aggregates are removed by a 0.45 µm polyethersulfone clarifying filter, followed by a 0.22 µm sterilising-grade membrane. The solution is buffered with 0.02 M citrate-phosphate to pH 5.0–6.0, because below pH 3.5 oxidative loss of quercitrin and rutin accelerates, while above pH 7.0 flavonoid aglycones precipitate as coarse flakes. Filled vials intended for swine respiratory disease complex are subjected to autoclaving at 121 °C for 15 min; this terminal cycle may reduce the houttuyfonin marker by 3–5%, so aseptic filling is preferred when the finished label claim has no overage. The solution is tested for sterility per USP <71>, bacterial endotoxins per USP <85> with an acceptance limit of <0.5 EU/mg of dry extract, and particulate matter per USP <788>; for a 10 mL vial, counts of particles ≥10 µm must not exceed 6000 per container and particles ≥25 µm must not exceed 600 per container. In-use compatibility in 0.9% sodium chloride and 5% dextrose is generally acceptable for 24 h at 25 °C, but dilution into sodium bicarbonate or lactated Ringer’s solutions above pH 7.4 produces turbidity and should be avoided because the ionised phenolic fraction forms poorly soluble calcium and sodium complexes. Published pharmacokinetic data in swine for this exact injection-grade API is limited, so the labelled dose, injection site, and withdrawal period must be derived from target-animal safety and residue depletion studies conducted on the final registered product.

How Does Drinking-Water Chlorination Affect a Soluble Powder That Contains Houttuynia-Derived Phenolics?

The first manufacturing hurdle is not API potency but the interaction between residual chlorine and unsaturated oxygenated components. Free chlorine at 2–4 mg/L oxidises 2-undecanone and related volatile fractions; oxidation products are less soluble and form surface films on bulk tanks. To mitigate, formulators blend the extract at 10–20% w/w active content on a carrier of anhydrous glucose and sodium chloride, adding colloidal silicon dioxide at 0.5–1.5% w/w to stabilise dust and flow. The dry powder is mixed in a ribbon blender at 25 rpm for 10 min; batch uniformity is tested by HPLC for total flavonoids with a coefficient of variation of <5% across 10 sampling points. Reconstitution in water at 25 °C and 500 mg/L CaCO₃ hardness with 600 rpm stirring for 2 min must pass a 75 µm sieve; when water temperature falls below 10 °C, dissolution time doubles and a 35 °C pre-mix step of 15 min is used. For farms where free chlorine exceeds 3 mg/L, sodium metabisulfite may be added at 0.2–0.5% w/w, but only after forced-degradation testing at 40 °C/75% RH for 4 weeks demonstrates that the bisulfite adduct does not displace the native houttuyfonin marker. Medicated water should be freshly prepared; after 24 h in water with bicarbonate alkalinity above 350 mg/L, total flavonoid retention can drop by 8–12% due to alkaline hydrolysis. Microbiological quality of the dry powder is controlled by USP <61> and USP <62>, with absence of Escherichia coli and Salmonella. Water proportioner calibration is performed with a methylene blue tracer at 1–5% stock solution ratio, and the final drinking-water concentration is set by the registered formulation, typically in the range of 100–250 g of a 10% w/w active extract powder per 1000 L of drinking water.

Feed premix conversion is more sensitive to moisture and thermal history than aqueous processing. The extract is first diluted to a 1:10 carrier premix with defatted rice bran or low-moisture corn starch; release moisture must remain below 5.0% w/w because the residual carbohydrate fraction becomes sticky above 60% RH and forms lumps in multiwall bags. For granulated feeds, a top-spray fluidised-bed granulator with inlet air 55–65 °C and product temperature 34–38 °C is preferred; aqueous binder solution based on 5% w/w povidone K30 or hydroxypropyl methylcellulose is sprayed at 8–12 g/min per kg of dry powder, and exhaust humidity is held at 18–22% RH. Direct pelleting through a steam conditioner above 70 °C is not recommended for unprotected extract because volatile 2-undecanone fractions are lost, and the remaining flavonoids can bind to calcium-montmorillonite carriers. If the API must be included in pelleted feed, microencapsulation with hydrogenated palm stearin melting at 58–61 °C before pelleting is the standard approach; pellet durability and marker retention are then evaluated. Blending studies in double-ribbon mixers produce acceptable uniformity only when the extract premix is added after the main ingredients have been mixed for 5 min; final mixer validation uses HPLC total flavonoid content at 10 sampling points with CV <5%. Bitter-tasting fractions reduce voluntary feed intake in nursery pigs; sodium saccharin at 0.05–0.1% w/w or a dry licorice powder may be included if the regulatory formula permits. Accelerated stability at 40 °C/75% RH for 6 months should be part of every new carrier qualification because published data for this specific API on different carriers is limited. Avoid bentonite, zeolite, or high-calcium oxide carriers above 2% w/w, as the ion-exchange capacity binds phenolic acids and reduces extractable marker content.

Tablet Compression and Capsule Filling of the Spray-Dried Extract for Companion Animal Dosage Forms

Tablet compression and capsule filling of the spray-dried extract for companion animal dosage forms require the formulator to manage poor flow and high hygroscopicity rather than drug-loading capacity. The spray-dried extract typically has a Hausner ratio above 1.30 and Carr’s index above 28, so direct compression is not robust; roller compaction or wet granulation is used. A validated tablet blend contains microcrystalline cellulose at 30% w/w, lactose monohydrate at 20% w/w, croscarmellose sodium at 3% w/w, colloidal silicon dioxide at 1% w/w, and magnesium stearate at 0.5% w/w. Magnesium stearate lubrication must be limited to 3–5 min in a bin blender at 15–20 rpm; over-lubrication beyond 10 min delays disintegration beyond 15 min in 0.1 M hydrochloric acid and creates tablets that fail USP <701>. Compression on an 11 mm round flat-faced bevel-edge tooling at 15–25 kN produces hardness of 70–110 N and friability below 0.8%. A hydroxypropyl methylcellulose film coat at 3% w/w total weight gain isolates the core from ambient moisture and improves patient acceptance. Capsule filling with HPMC shells, size 2, requires a blend moisture level below 4% w/w and a fill weight of 200–250 mg; the exact extract content per unit is calculated from the desired crude herb equivalent and must be supported by batch assay. Enteric coating is not recommended unless a pH-specific dissolution profile is proven, because the flavonoid fraction has variable release in simulated intestinal fluid at pH 6.8. Published data for this specific companion animal formulation is limited; therefore, each manufacturer should qualify the dissolution or disintegration profile in the intended product, not rely on compendial monograph limits alone.

Intramammary and intrauterine presentations are the most demanding non-systemic sterile forms because the product contacts inflamed mucosal tissue and must remain particle-free after freeze-thaw and pressure changes during infusion. The API is dissolved in a sterile buffered vehicle at pH 5.5–6.0 using phosphate buffer; the solution is then passed through 0.45 µm and 0.22 µm polyethersulfone filters under nitrogen pressure. Aseptic filling is carried out in an ISO 14644-1:2015 class 5 unidirectional-airflow cabinet; the peristaltic filling pump must hold fill accuracy within ±2% of the 10 mL labelled volume. For intramammary syringes, bacterial endotoxin is controlled to <0.1 EU/mL of final product because the intramammary tissue is sensitive to endotoxin-mediated inflammation; this is tighter than the API release limit used in systemic injections. Syringe packages are checked by vacuum bubble leak test according to ASTM D3078. The product should not be frozen; one freeze-thaw cycle can produce crystalline precipitate and needle channel blockage. In dairy cattle, the infusion is administered after complete milking, and the milk withdrawal period is established by residue depletion, not by the API supplier. For intrauterine use, a 50 mL or 100 mL aqueous solution is mixed with sterile saline before infusion; the final pH should remain between 5.0 and 6.0, and dilution with lactated Ringer’s longer than 4 h is not recommended because calcium ions can form weak complexes with polyphenolic acids. Sterility is tested per USP <71>, particulate matter per USP <788>, and package integrity per ASTM D3078. Operators should avoid siliconised syringes if the formulation contains polysorbate 80, because surfactant migration can alter the silicone layer and increase subvisible particle counts after 7 days of storage.

When the Injection-Grade API Is Repurposed for Neonatal Drench Solutions

Neonatal drench solutions do not require sterility but take advantage of the injection-grade API’s low endotoxin and low bioburden specifications when administered to pre-ruminant calves or lambs with immature gut barriers. A non-sterile oral solution is compounded with purified water, potassium sorbate 0.1% w/w, citric acid 0.2% w/w, sodium citrate 0.3% w/w, and glycerol 0.5% w/w; the target pH is 4.2–4.8 to suppress microbial growth and maintain dissolution of organic acid constituents. The liquid is prepared at 35 °C with slow agitation, cooled to room temperature, and filled into amber PET bottles. Pasteurisation at 63 °C for 30 min is used when terminal filtration is not available; high-temperature short-time processing above 85 °C is avoided because the phenolic marker degrades and the solution darkens. Drench nozzles must be calibrated before each batch; for a 2.5–5.0 mL dose volume, the coefficient of variation across 20 pump actuations should be under 3%. The oral bioavailability of houttuyfonin in pre-ruminant calves has not been fully characterised in peer-reviewed literature; therefore, the product should be registered on the basis of target-animal safety and clinical efficacy studies with the finished solution. The solution should not be combined with strong alkaline electrolytes or activated charcoal; co-administration with milk replacer may reduce contact time with the intestinal epithelium and alter absorption, but published data for this specific configuration is limited.